Showing 1 - 10 of 17
Persistent link: https://www.econbiz.de/10009234148
Do stronger intellectual property rights incentivize female participation in innovation? We provide new evidence on this question using a unique database of artificial intelligence patents publicly shared by the USPTO. Our identification strategy leverages China's WTO TRIPs accession, which led...
Persistent link: https://www.econbiz.de/10014576575
Persistent link: https://www.econbiz.de/10008647604
Persistent link: https://www.econbiz.de/10010530696
Persistent link: https://www.econbiz.de/10012039349
Existing research has focused on why and when firms may choose to access the external technology market. Surprisingly, however, less is known about the reliability of the patents attached to these external technologies in the face of litigation. “Weak” external patents expose a firm to the...
Persistent link: https://www.econbiz.de/10013012011
Existing research has focused on why and when firms may choose to access the external technology market. Surprisingly, however, less is known about the reliability of the patents attached to these external technologies in the face of litigation. “Weak” external patents expose a firm to the...
Persistent link: https://www.econbiz.de/10013024153
This paper uses data on transactions in the pharmaceutical industry to examine the demand-side of technology outsourcing. By integrating a transaction-cost economics perspective with the analysis of internal Ramp;D capabilities, we find that firms with relatively more cospecialized complementary...
Persistent link: https://www.econbiz.de/10012707435
This article uses data on transactions in the pharmaceutical industry to examine the demand-side of technology outsourcing. By integrating a transaction-cost economics perspective with the analysis of internal R&D capabilities, we find that firms with relatively more cospecialized complementary...
Persistent link: https://www.econbiz.de/10013038800
We evaluate the welfare effects of differential pricing, voluntary licensing, and compulsory licensing in the Indian market for oral anti-diabetic (OAD) drugs. This market includes a new class of molecules called DPP-4 inhibitors, all of which are under patent protection in India. The Indian...
Persistent link: https://www.econbiz.de/10013035611